Multifunctional Opioid Receptor Agonism and Antagonism by a Novel

Macrocyclic Tetrapeptide Prevents Reinstatement of Morphine-Seeking Behavior

Ariana C. Brice-Tutt¹, Lisa L. Wilson¹, Shainnel O. Eans¹, Heather M. Stacy¹, Chloe A.

Simons¹, Grant Simpson², Jeremy S. Coleman², Michael J. Ferracane²⁺, Jane V.

Aldrich² and Jay P. McLaughlin¹

Appendix S1: Specific numbers of mice used across experiments:

Animals were not re-used across different experiments, but time points from the same experiments <u>are</u> displayed across several figures as needed to clarify the characterization. Use of the animals by experiment is listed in the following table:

| C57BJ/6 | | | MOPr KO | | KOPr KO | | DOPr KO | | |
|--|---|---|--|--|--|--|--|--|--|
| <i>cyclo</i> [Pro- Sar-Phe-D- Phe] | Vehicle | Opioid Controls | <i>cyclo</i> [Pro- Sar-Phe- D-Phe] | Vehicle | <i>cyclo</i> [Pro- Sar-Phe- D-Phe] | Vehicle | <i>cyclo</i> [Pro- Sar-Phe- D-Phe] | Vehicle | Total per Figure: |
| 92* | 8 | | | | | | | | 100 |
| 22 | 7 | | | | | | | | 29 |
| 16 | | | 8 | | 8 | | 8 | | 40 |
| 32 | | 48† | | | | | | | 80 |
| 24* + 15 | | 16† | | | | | | | 55 |
| 16* | | 16† | | | | | | | 32 |
| 8 | | 16† | | | | | | | 24 |
| 8 | 32 | 8 | | | | | | | 48 |
| 22 | 39 | 16 | 17 | 24 | 16 | 20 | | | 154 |
| 41 | 21 | 47 | | | | | | | 109 |
| 96 | 94 | 12 | | | | | | | 202 |
| 21 | 20 | 14 | | | | | | | 55 |
| 739 | | 49 | | 44 | | 8 | | 840 | |
| | cyc/o[Pro- Sar-Phe-D- Phe] 92* 22 16 32 24* + 15 16* 8 8 8 22 41 96 21 | cyc/o[Pro- Sar-Phe-D- Phe] Vehicle 92* 8 22 7 16 - 32 - 24* + 15 - 16* - 8 32 22 39 41 21 96 94 21 20 | cyc/o[Pro- Sar-Phe-D- Phe] Vehicle Opioid Controls 92* 8 - 22 7 - 16 - - 32 48 [†] - 24* + 15 - 16 [†] 16* - 16 [†] 8 32 8 22 39 16 41 21 47 96 94 12 21 20 14 | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | cyc/o[Pro- Sar-Phe-D- Phe] Vehicle Opioid Controls cyc/o[Pro- Sar-Phe- D-Phe] Vehicle 92* 8 22 7 16 8 32 48 [†] 24* + 15 16 [†] 16* 16 [†] 8 32 8 8 32 8 22 39 16 17 24 41 21 47 96 94 12 21 20 14 | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | cyclo[Pro- Sar-Phe-D- Phe]Vehiclecyclo[Pro- Sar-Phe- D-Phe]Vehiclecyclo[Pro- Sar-Phe- D-Phe]Vehiclecyclo[Pro- Sar-Phe- D-Phe]VehicleVe |

(blue* = additional data from mice also shown in figure 2A; blue[†] = data from the 16 U50,488 controls shown in figure 4A)






Figure S1. Antinociceptive activity of morphine following administration i.c.v. **(A)** or i.p. **(B)** in the 55°C warm-water tail-withdrawal assay in C57BL/6J mice. Morphine demonstrated significant time- and dose-dependent antinociception with repeated measurement over time. Points represent average % antinociception ± SEM from 8 mice for each set (16 for 10 mg·kg⁻¹ i.p.) presented for a total of 63 C57BL/6J mice.